Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy

Abstract

The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete response from advanced ovarian cancer following front-line platinum-based therapy were retrospectively analyzed. The patients treated with HMM were compared to the patients of matched counterpart without consolidation therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment. For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235). No treatment-related adverse events were reported during the follow-up period. Although this study failed to show the significant survival benefit of consolidation therapy with HMM in patients with advanced EOC, we consider that our study can contribute data to investigate the effectiveness of consolidation therapy in epithelial ovarian cancer.

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer

“…The SLR search terms are listed in Supplementary Tables S1–S3 . Trials evaluating chemotherapeutic agents given as maintenance therapy, such as paclitaxel, paclitaxel poliglumex, topotecan, or hexamethylmelamine, were excluded because the intent was to evaluate maintenance therapy following active chemotherapy treatment and not continued chemotherapy [ 28 , 29 , 30 , 31 , 32 ]. Additional details on the SLR methodology and outcomes are reported separately [ 33 ].…”

Μελέτη Του Ανοσοποιητικού Συστήματος Και Των Παραμέτρων Του Σε Ογκολογικούς Ασθενείς Μετά Τη Χορήγηση Ταξανών Και Πλατινούχων Σκευασμάτων

“…Η εξαµεθυλµελαµίνη χορηγείται από του στόµατος σε δόση 4-12 mg/Kg ηµερησίως επί 14 ή 21 ηµέρες. Χορηγείται σε νεοπλασίες των ωοθηκών, του µαστού, σε λεµφώµατα και µικροκυτταρικό καρκίνο του πνεύµονα205 .Παρενέργειες από την χορήγηση της ΗΜΜ είναι η ναυτία και οι έµετοι. Επίσης το φάρµακο παρουσιάζει σηµαντική νευροτοξικότητα.…”